Raymond James Trust N.A. Makes New $211,000 Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Raymond James Trust N.A. acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 1,072 shares of the medical research company’s stock, valued at approximately $211,000.

Other institutional investors have also added to or reduced their stakes in the company. Tidal Investments LLC lifted its position in Charles River Laboratories International by 99.8% during the 1st quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock worth $1,435,000 after acquiring an additional 2,646 shares during the period. Comerica Bank lifted its stake in shares of Charles River Laboratories International by 5.6% in the first quarter. Comerica Bank now owns 17,514 shares of the medical research company’s stock worth $4,745,000 after buying an additional 927 shares in the last quarter. Atria Investments Inc grew its position in shares of Charles River Laboratories International by 19.6% in the first quarter. Atria Investments Inc now owns 17,502 shares of the medical research company’s stock valued at $4,742,000 after purchasing an additional 2,873 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of Charles River Laboratories International by 223.4% during the 1st quarter. Cetera Investment Advisers now owns 9,740 shares of the medical research company’s stock valued at $2,639,000 after acquiring an additional 6,728 shares during the last quarter. Finally, Cetera Advisors LLC increased its holdings in shares of Charles River Laboratories International by 197.1% during the 1st quarter. Cetera Advisors LLC now owns 3,357 shares of the medical research company’s stock worth $910,000 after buying an additional 2,227 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Price Performance

CRL stock opened at $199.59 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock’s 50 day moving average price is $194.64 and its 200 day moving average price is $205.19. The firm has a market cap of $10.21 billion, a P/E ratio of 24.98, a PEG ratio of 5.19 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the previous year, the company earned $2.72 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has approved a share buyback program on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 9.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several research analysts have weighed in on CRL shares. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research note on Monday, November 18th. JPMorgan Chase & Co. lowered Charles River Laboratories International from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $270.00 to $205.00 in a report on Thursday, August 8th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Finally, Bank of America cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and a consensus price target of $214.38.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).